Pharma Focus Europe

Mymetics and PCI Biotech Sign a Preclinical Research Collaboration

Thursday, September 01, 2022

Mymetics Corporation a pioneer in the research and development of virosome based vaccines and immunotherapies against infectious and life disabling diseases, and PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharmaceutical company, have entered into a preclinical research collaboration with the aim to explore technological synergies for the possible enhancement of cancer therapy.

The project is the first step in determining if there is a basis for a further collaboration between Mymetics and PCI Biotech, of short duration and without immediate commercial impact for either of the parties involved.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva